Propranolol

Propranolol
Formula	C16H21NO2
Class	Nonselective beta blocker
Administration	Oral, intravenous, topical (ophthalmic, off-label)
Solubility	Free base poorly water-soluble; the hydrochloride salt is water-soluble
Legal status	Prescription (Rx)
Brand names	Inderal, Inderal LA, Innopran XL, Hemangeol
Bioavailability	~25% oral (extensive first-pass liver metabolism; protein-rich food raises it)
Recommended dose	40-320 mg/day divided, indication-dependent
Upper limit	320 mg/day for hypertension/angina; up to 800 mg/day used in essential-tremor dose-finding trials
LD50	Mice: 565 mg/kg after oral route 22 to 35 mg/kg after intravenous route 107 mg/kg after intraperitone al route (RETCS, 1985)
Ray's verdict	Depends on context Useful short-term for blunting adrenaline's tissue-damaging effects (racing heart, stress-driven bone loss, traumatic memory reconsolidation), but chronic use lowers T3 and raises reverse T3, so it should not substitute for correcting the hypothyroidism or stress that is raising adrenaline in the first place.

Propranolol is a nonselective beta-adrenergic receptor blocker approved for hypertension, angina, arrhythmia, migraine prevention, essential tremor, and, as an oral solution, infantile hemangioma. It blocks the tissue effects of adrenaline (epinephrine) and noradrenaline at both beta-1 and beta-2 receptors, and because it is lipophilic enough to cross into the brain, it blunts central as well as peripheral catecholamine signaling. Ray Peat's references to propranolol are narrow and specific: slowing a racing heart in hyperthyroidism, blocking adrenaline-driven bone loss, and preventing coronary vasospasm, alongside the drug's separate, well-studied use for blocking the emotional reconsolidation of traumatic memory.

Structure / Chemical properties

Propranolol (C₁₆H₂₁NO₂, molecular weight 259.34) is an aryloxypropanolamine, structurally related to isoproterenol but acting as an antagonist rather than an agonist at beta-adrenergic receptors. It is one of the most lipophilic beta blockers in clinical use, which lets it cross the blood-brain barrier and the placenta freely, unlike more polar beta blockers such as atenolol. Oral bioavailability is low (roughly 25%) because of extensive first-pass hepatic metabolism via CYP2D6, and its main metabolite, 4-hydroxypropranolol, is itself pharmacologically active and longer-lived (half-life 5-7.5 hours) than the parent drug (half-life 3-6 hours).

Function / Mechanism of action

Propranolol competitively blocks beta-1 receptors (heart, kidney) and beta-2 receptors (airway smooth muscle, blood vessels, liver, uterus) without selectivity between them. Blocking beta-1 receptors reduces heart rate, contractility, and AV-node conduction; blocking beta-2 receptors removes catecholamine-driven bronchodilation and vasodilation, which is why it can worsen asthma and why some patients get cold hands and feet. At doses above what is needed for receptor blockade it also has a mild membrane-stabilizing, quinidine-like effect on cardiac tissue.

Propranolol will slow a rapid heart.

— Ray Peat

Propranolol also inhibits type 1 deiodinase, the enzyme that converts T4 to the active T3 outside the thyroid gland; it lowers plasma T3 and raises reverse T3 (rT3) in a dose-dependent way. This is useful acutely in hyperthyroidism, where excess T3 is already the problem, but a rising rT3/T3 ratio is a marker of tissue hypothyroidism and slowed metabolism, not a neutral side effect, which limits propranolol's role to short-term symptom control rather than ongoing use.

Medical uses / Effects

Thyrotoxicosis and hyperthyroid tachycardia

Propranolol is the preferred beta blocker for thyroid storm and hyperthyroid tachycardia specifically because, on top of ordinary beta-1 blockade, it also blunts peripheral T4-to-T3 conversion. Ray Peat recommended it for exactly this narrow purpose: controlling a racing heart while the underlying goiter or excess iodine issue resolves, not as a long-term thyroid treatment.

Coronary vasospasm

An early physiological review Peat cited found that acute coronary constriction following hypoxic perfusion could be prevented by progesterone but not by estradiol or testosterone, and that among prostaglandin-synthesis antagonists, "chloroquine, procaine and propranolol can all behave as PG antagonists" capable of preventing or reversing the constriction. Peat's framing puts propranolol alongside aspirin-type drugs as a secondary tool for coronary constriction, with progesterone as the physiological answer.

Migraine prophylaxis

Propranolol is a first-line drug for migraine prevention, with decades of placebo-controlled trial support and low cost; a 2024 European Headache Federation re-appraisal confirmed an acceptable tolerability profile alongside proven efficacy. The proposed mechanism is blockade of beta-1 receptors in the trigeminovascular pathway and stabilization of the sympathetic fluctuations linked to vascular instability in migraine, though the precise mechanism is still debated. The FDA label sets an initial dose of 80 mg/day, with an effective range of 160-240 mg/day.

A related topical approach uses timolol, a beta blocker of the same class, as an eyedrop for acute migraine rather than prevention. A randomized, placebo-controlled crossover trial (n=50) found that one drop of 0.5% timolol maleate ophthalmic solution in each eye at migraine onset produced a 4-point or greater drop in pain score, or a pain-free result, within 20 minutes in 82% of attacks, versus 14% for placebo (P<0.001). This suggests topical beta blockade could be a fast, non-oral option for an acute attack, using the same mechanism oral propranolol uses for prevention.

Essential tremor

Propranolol is a first-line drug for essential tremor. A double-blind, placebo-controlled trial found that a single 120 mg oral dose reduced tremor amplitude by 43% within hours. Benefit with sustained dosing is dose-dependent rather than fixed; the FDA label lists 120 mg/day as the typical effective dose, with some patients needing 240-320 mg/day.

Trauma and fear-memory reconsolidation

Propranolol's ability to interrupt memory reconsolidation of fear and trauma is one of the applications Ray Peat's network highlighted most, and it remains scientifically contested. A single 40 mg oral dose, given within roughly an hour before or after a traumatic memory is reactivated, was shown in one trial to selectively erase the emotional charge of that memory while leaving the factual content intact, an effect that required a full night's sleep afterward for consolidation. A broader 2025 systematic review and meta-analysis of seven clinical studies found a statistically significant, moderate-sized reduction in PTSD symptom severity with propranolol treatment. However, a separate 2022 re-analysis that corrected methodological errors in an earlier meta-analysis and included unpublished trials found no significant effect of propranolol over placebo specifically on memory-reconsolidation disruption, arguing the clinical evidence for that specific mechanism is weaker than the original single-study reports suggested.

A single 40-mg dose of oral propranolol, judiciously timed, constitutes an outside-the-box yet highly promising treatment for anxiety disorders, and perhaps for posttraumatic stress disorder as well.

— Marieke Soeter, PhD

A separate, controlled single-dose trial found blocking adrenaline activity with 40 mg propranolol significantly improved conversational reciprocity scores (staying on topic, turn-taking, nonverbal communication) in 20 individuals with autism compared to placebo.

Performance anxiety and stress ulcers

Propranolol is used off-label for situational (performance) anxiety, where it blunts the physical symptoms of an adrenaline surge (racing heart, tremor, sweating) without the sedation of a benzodiazepine. In rat studies of stress-induced gastric ulceration, propranolol (1 and 10 mg/kg) potentiated ulcer severity rather than protecting against it, while the beta-agonist isoproterenol had the same effect, an apparent paradox the authors attributed to disruption of the normal catecholamine balance during acute stress rather than to any single receptor's action.

Bone and immobility stress

Ray Peat noted that the bone loss caused by immobility, which he attributed to stress-driven adrenaline, "can be blocked by an adrenaline blocker such as propranolol." Adrenaline, raised by stress, aging, and hypothyroidism, lowers carbon dioxide and raises lactic acid and parathyroid hormone, all of which favor bone resorption. A mouse study found the same mechanism explains why long-term SSRI use causes bone loss: the antidepressant fluoxetine raises central sympathetic (adrenaline) output enough to override its own local anti-resorptive effect on bone, and co-treatment with propranolol prevented the bone loss without blocking the drug's behavioral effect.

Portal hypertension and variceal bleeding

Outside the stress/adrenaline framework, propranolol is also a mainstay of hepatology: nonselective beta blockade lowers portal pressure by reducing cardiac output (beta-1) and causing splanchnic vasoconstriction (beta-2), and it is first-line for preventing a first or repeat variceal bleed in cirrhosis.

Alcohol withdrawal

Beta blockers including propranolol have been used off-label alongside drugs like clonidine and cyproheptadine for alcohol-withdrawal symptoms.

Side / Adverse effects

• Bradycardia and AV block from beta-1 blockade; contraindicated with pre-existing bradycardia or heart block.
• Bronchospasm from unopposed beta-2 blockade in airway smooth muscle; contraindicated in asthma and reactive airway disease, though small trials suggest low-dose, cautious use may be better tolerated in mild asthma than once assumed.
• Cold extremities from loss of beta-2-mediated vasodilation, leaving alpha-adrenergic vasoconstriction unopposed.
• Hypoglycemia masking, because beta blockade blunts the adrenaline-driven warning signs (tremor, palpitations) of low blood sugar, particularly relevant for diabetics.
• Fatigue, sleep disturbance, and vivid dreams, attributed to propranolol's high lipophilicity and consequent central-nervous-system penetration, more prominent than with hydrophilic beta blockers like atenolol.
• Depression is not clearly caused by propranolol. A 2021 systematic review and meta-analysis of psychiatric adverse events across beta-blocker trials found depression was the most frequently reported psychiatric complaint but did not occur more often on a beta blocker than on placebo.
• Lowered T3 / raised reverse T3 with sustained use, from type 1 deiodinase inhibition; a specific caution for anyone not being treated for active hyperthyroidism.
• Fetal growth restriction in pregnancy has been reported with beta-blocker use in pregnant women with cardiovascular disease, though the risk varies by specific drug; propranolol's risk profile in this data was intermediate between atenolol (highest) and bisoprolol (lowest).
• Rebound tachycardia and hypertension on abrupt discontinuation after regular use; dose should be tapered over one to two weeks rather than stopped suddenly.
• Overdose can cause severe bradycardia, hypotension, seizures, and ventricular arrhythmias from propranolol's membrane-stabilizing effect; standard treatment includes glucagon, high-dose insulin/glucose, and sodium bicarbonate for QRS widening.

Dosing

Dose is indication-specific rather than a single standard amount, per FDA-approved labeling:

• Hypertension: 40 mg twice daily initially, maintenance typically 120-240 mg/day divided.
• Angina: 80 mg/day divided into 2-4 doses, titrated up to a maximum of 320 mg/day.
• Migraine prophylaxis: 80 mg/day in 2 divided doses, increased as needed to 160-240 mg/day.
• Essential tremor: 40 mg twice daily initially; 120 mg/day is the typical effective dose, with some patients needing 240-320 mg/day.
• Hyperthyroid tachycardia / thyroid storm: short-term, symptom-guided dosing to control heart rate, discontinued once the hyperthyroidism resolves.
• Variceal bleeding prophylaxis: typically titrated to reduce resting heart rate by about 25%, with an effective dose of at least 80 mg/day associated with reduced bleeding risk.
• Single-dose fear-memory reconsolidation protocols (research use): a single 40 mg oral dose, timed within about an hour before or after memory reactivation, followed by a full night's sleep.

Abrupt discontinuation after regular use should be avoided; the dose is tapered down over one to two weeks.

Brands and sources

Marketed as Inderal and Inderal LA (extended-release), Innopran XL, and, as an oral solution for infantile hemangioma, Hemangeol. Generic propranolol is inexpensive and widely available; its low cost is part of why it remains in use for niche applications like fear-memory research despite the availability of newer drugs.

See also

• Adrenaline
• Stress
• Thyroid
• Hyperthyroidism
• T3
• Bone
• Anxiety
• PTSD
• Migraine
• Cortisol